Summary

The advancements in molecular techniques, discovery of recurrent molecular alterations, and development of targeted and immunotherapies has led to a more comprehensive understanding and personalized approach into the diagnosis and management of lung cancer. Prognostic biomarker testing may shed light into the tumor’s behavior regardless of therapy to help guide patient management. Predictive biomarker testing methods have specific assay-dependent requirements and is necessary for selection of the most appropriate patients for the most suitable therapies. The combination of molecular prognostication and predictive utility of biomarkers has made lung cancer a poster child for precision medicine in solid tumors.